Bond.az White LogoBond.az Black Logo

KeyBanc cuts Lowe's target to $275

KeyBanc cuts Lowe's price target to $275 from $300 but maintains Overweight rating due to market share gains.

Michael Brown
ByMichael Brown- Senior Editor
|
0

KeyBanc lowered its price target on Lowe's Companies Inc. (NYSE:LOW) to $275 from $300, while maintaining an Overweight rating. The home improvement retailer currently trades at $214.75 with a market cap of $120.8 billion.

Lowe's reported first-quarter earnings per share above expectations, with comparable sales roughly in line with consensus. Consumer spending trends remained resilient.

KeyBanc monitors rising interest rates and housing affordability challenges but remains positive on long-term housing recovery. Lowe's continues gaining market share in the professional contractor segment.

The company has raised its dividend for 42 consecutive years, with a yield of 2.17% and a P/E ratio of 18.46. Several other analysts, including RBC Capital, Wolfe Research, Wells Fargo, BofA Securities, and Mizuho, have also reduced their price targets for Lowe's.

More News
Today / 13:50
|
515

KeyBanc cuts Autodesk price target to $341

KeyBanc lowers Autodesk price target to $341 from $365, keeping Overweight rating. Stock at $235.11. Bond.az reports.

0
Today / 13:44
|
306

RBC Capital Reiterates Vertiv Stock Rating

RBC Capital reaffirms Vertiv's Outperform rating and $435 target, citing strong datacenter growth and ambitious 2030 goals.

0
Today / 11:34
|
389

Nouveau Monde Graphite Price Target Cut to $4.50

H.C. Wainwright cuts Nouveau Monde Graphite price target to $4.50. Stock trades at $1.97 as Matawinie mine construction begins.

0
Today / 11:33
|
796

Cantor Fitzgerald Reaffirms Nvidia Overweight Rating

Cantor Fitzgerald reaffirms Nvidia Overweight rating, $350 target. Strong data center growth drives performance.

0
Today / 11:32
|
645

Belite Bio Stock Rises on NDA Progress

Belite Bio stock rises as H.C. Wainwright reiterates Buy rating and NDA progresses. Tinlarebant potential FDA approval expected in Q1 2027.

0
Today / 11:31
|
420

H.C. Wainwright Raises Immunovant Target to $40

H.C. Wainwright raises Immunovant price target to $40 from $35 after positive Phase 2 RA data, maintains Buy rating.

0
Today / 11:21
|
614

Applied Digital Price Target Raised to $66

Needham raises Applied Digital price target to $66 after a major 300MW lease agreement. Strong growth outlook.

0
Today / 11:00
|
299

Wolfe Research Cuts Lowe's Price Target on Weak Demand

Wolfe Research lowers Lowe's price target to $254 on muted demand outlook, maintaining Outperform rating.

0
Today / 09:21
|
578

UBS Upgrades Sumco Stock Rating

UBS upgraded Sumco Corp to Neutral with a new price target of JPY 3,100. Get the latest Sumco stock news on Bond.az.

0
Today / 09:20
|
523

Barclays Reiterates Overweight on Nvidia with $275 Target

Barclays reiterates Overweight rating on Nvidia stock with a $275 price target after strong quarterly results and raised guidance.

0
Today / 08:42
|
674

Raymond James Downgrades NOG Stock Rating

Raymond James downgrades NOG from Strong Buy to Outperform. Price target lowered to $35.

0
Today / 08:14
|
515

Jefferies downgrades ZoomInfo stock on AI

Jefferies downgrades ZoomInfo to Hold, cuts price target to $4.00 on weak demand and AI adoption headwinds.

0
...